Skip to main content
. Author manuscript; available in PMC: 2021 Jul 9.
Published in final edited form as: ACS Appl Bio Mater. 2020 Dec 24;4(1):229–251. doi: 10.1021/acsabm.0c01145

Figure 7.

Figure 7.

Peptide-modified nanocarriers were able to lower the effective dosage and the toxicity of the drug AmB. (A) Change in mouse lesion size over time for the following treatments: untreated (none), low dose of AmB drug (AmB6.25), low doses of AmB drug encapsulated in an unmodified nanoparticle (AmB6.25/ScrDR), full (high) dose AmB drug (AmB37.5), and low dose of AmB drug in the modified nanoparticle (AmB/PDD). From this graph, it can be seen that the low dose in the modified nanoparticle was the most effective at reducing lesion size. (B) Drug delivered in the modified nanoparticle has the highest percent inhibition, despite using a lower dose. (C) When encapsulated by the modified nanoparticle, the cytotoxicity of the drug is much lower. Reprinted with permission from ref 160. Copyright 2013 Oxford University Press.